Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years old who weigh ≥60 kg and have an initial BMI corresponding to obesity based on international cut-offs.
Victoza, a formulation of liraglutide used in diabetes, is indicated as an adjunct to diet and exercise to improve glycemic control in patients ≥10 years old with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease.
Liraglutide is also available in combination with insulin degludec as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.
Chinese People's Liberation Army General Hospital, Peking, Beijing, China
Novo Nordisk Investigational Site, Uppsala, Sweden
University Medical Center Ljubljana, Ljubljana, Slovenia
Hospital Universitari Vall d´Hebrón, Barcelona, Spain
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain
Hamad Medical Corporation, Doha, Qatar
Novo Nordisk Investigational Site, Lincoln, Nebraska, United States
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates
Investigational Site Number 8400033, Baltimore, Maryland, United States
Investigational Site Number 8400079, Albany, New York, United States
Investigational Site Number 8400019, Columbus, Ohio, United States
Diabetes Unit E. Wolfson Hospital, Holon, Tel Aviv, Israel
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.